Key Market Indicators
Czech sales of antihypertensive medicines are projected to reach around $37 million by 2026, up from $36 million in 2021. This represents an average annual growth rate of 0.8%. Since 1995, demand for these medicines in the Czech Republic has grown by an average of 4.9% each year. In 2021, the country was ranked tenth in the world for antihypertensive medicine sales, slightly behind Sweden, which had sales of $36 million. Italy, Spain and Australia took the second, third and fourth spots, respectively.
